The Online Investor
Drugs & Pharmaceuticals M&A image Drugs & Pharmaceuticals M&A » By The Online Investor Staff, updated Tue., Dec. 6, 9:35 AM Recent mergers and acquisitions in the Drugs & Pharmaceuticals M&A category.

Slide #56. The Medicines Company Rempex Pharmaceuticals, Inc.

Acquirer: The Medicines Company (MDCO)
Acquiree: Rempex Pharmaceuticals, Inc.
Details: The Medicines Company announced that it has acquired Rempex Pharmaceuticals, Inc., a company with multiple potential new therapies focused on multi-drug resistant gram-negative bacteria. The Medicines Company paid Rempex equity holders $140 million in an upfront payment at the closing of the deal. In addition, The Medicines Company has agreed to pay Rempex equity holders milestone payments subsequent to the closing, including certain development and regulatory approval milestones totaling $214 million, and commercial milestones totaling $120 million. The Medicines Company has acquired several anti-infective assets as a result of the transaction: Carbavance, Minocin IV, RPX-602, and a preclinical developmental program of novel investigational agents.

Medicines is a biopharmaceutical company. Co. is focused on inclisiran, the investigational RNA interference therapeutic, that inhibits production of proprotein convertase subtilisin/kexin type 9, a main protein that controls low-density lipoprotein-cholesterol levels. Co. has the right to develop, manufacture and commercialize inclisiran under its collaboration agreement with Alnylam Pharmaceuticals, Inc.

Open the MDCO Page at The Online Investor »

Company Name: 
Medicines Co (The)
Website: 
www.themedicinescompany.com
Sector: 
Drugs & Pharmaceuticals
 

Open the MDCO Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree MDCO Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Hold (2.44 out of 4)
100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Drugs & Pharmaceuticals M&A - Slide 56 of 100 Page | www.TheOnlineInvestor.com

Copyright © 1998 - 2022, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.